XML 21 R9.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions | 6 Months Ended
--- | ---
Jun. 30, 2018
Business Combinations [Abstract] |
Acquisitions | Acquisitions Bridgemedica, LLC On February 22, 2018, we completed the acquisition of 100% of the assets of Bridgemedica, LLC (“Bridgemedica”). For accounting purposes, Bridgemedica meets the definition of a business and has been accounted for as a business combination. Bridgemedica is a medical device company that provides concept to supply solutions through design, development engineering and manufacturing. Operating results of Bridgemedica are reported prospectively in our Life Sciences group after the acquisition date. We have finalized certain working capital adjustments and are in the process of completing the integration of the Bridgemedica business into our operations. Amounts recorded for preliminary goodwill and intangible assets are disclosed in Note 6 and Note 7, respectively, and are subject to completion of our integration procedures. Paragon Medical, Inc. On May 7, 2018, we acquired 100% of the stock of PMG Intermediate Holding Corporation, the parent company of Paragon Medical, Inc. (“Paragon Medical”) for a base purchase price of $375.0 million in cash, subject to certain adjustments. After estimated working capital and other closing adjustments, the cash purchase price was approximately $391.0 million which included $13.4 million in cash acquired. We paid cash of $392.2 million and recorded a receivable of approximately $1.3 million in other current assets for the balance. For accounting purposes, Paragon Medical meets the definition of a business and has been accounted for as a business combination. Paragon Medical is a medical device manufacturer which focuses on the orthopedic, case and tray, implant and instrument markets. This acquisition continues our strategic focus to expand our Life Sciences portfolio as well as create a balanced business by diversifying our products and finished device offerings. Operating results of Paragon Medical are reported prospectively from the date of acquisition in our Life Sciences group. We have performed a preliminary assessment of the opening balance sheet and purchase price allocation which is subject to completion of working capital adjustments and fair value estimates. Opening balance sheet deferred taxes have been recorded based on estimates made as of the acquisition date as well as information currently available to management. As estimates are refined and additional information is received throughout the measurement period, adjustments to opening deferred taxes will be recorded with an offsetting adjustment to goodwill. We incurred new debt in connection with the Paragon Medical acquisition as described in Note 10. The following table summarizes the preliminary purchase price allocation for the Paragon Medical acquisition.
Fair value of assets acquired and liabilities assumed | May 7, 2018
Cash and cash equivalents | $ | 13,418 |
Accounts receivable | 22,853 |
Inventories | 23,606 |
Other current assets | 937 |
Property, plant and equipment | 69,322 |
Intangible assets subject to amortization | 164,200 |
Other non-current assets | 3,304 |
Goodwill | 157,421 |
Total assets acquired | $ | 455,061 |
Current liabilities | $ | 16,767 |
Deferred tax liability | 46,713 |
Other non-current liabilities | 620 |
Total liabilities assumed | $ | 64,100 |
Net assets acquired | $ | 390,961 |
A combination of income, market, and cost approaches were used for the valuation where appropriate, depending on the asset or liability being valued. Valuation inputs in these models and analyses gave consideration to market participant assumptions. Acquired intangible assets are primarily customer relationships. As of June 30, 2018, intangible assets in connection with Paragon Medical were $163.3 million after post-acquisition amortization. In connection with the Paragon Medical acquisition, we recorded goodwill, which represents the excess of the purchase price over the estimated fair value of tangible and intangible assets acquired, net of liabilities assumed. As of June 30, 2018, goodwill in connection with Paragon Medical was approximately $155.6 million after post-acquisition currency impacts. The goodwill is attributed primarily to Paragon Medical as a going concern, the assembled workforce, and the fair value of expected cost synergies, and revenue growth from combining the NN and Paragon Medical life sciences businesses. The going concern element represents the ability to earn a higher return on the combined assembled collection of assets and businesses of Paragon Medical than if those assets and businesses were to be acquired and managed separately. Approximately $2.8 million of the goodwill relates to prior asset acquisitions by Paragon Medical and is expected to be deducted for tax purposes. Property, plant and equipment acquired primarily included machinery and equipment for use in manufacturing operations. Additionally, manufacturing sites and related facilities, including leasehold improvements, were acquired. We have performed a preliminary assessment of the fair value of property, plant and equipment using both the cost approach and the market approach. The preliminary assessment was supported where available by observable market data which includes consideration of obsolescence. We have performed a preliminary assessment of the fair value of intangible assets using the income approach, supported by market data, by using the relief from royalty and multi-period excess earnings methods. We incurred approximately $4.9 million in acquisition related costs with respect to Paragon Medical during the six months ended June 30, 2018. Transaction costs were expensed as incurred and are included in the “Acquisition related costs excluded from selling, general and administrative expense” line item in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). We expensed $12.9 million of financing costs related to the Paragon Medical acquisition during the six months ended June 30, 2018, which are included in the "Loss on extinguishment of debt and write-off of debt issuance costs" line item in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). As required by the acquisition method of accounting, acquired inventories were recorded at their estimated fair value. Beginning May 7, 2018, our consolidated results of operations include the results of Paragon Medical. Since the date of the acquisition, net sales of $27.1 million and income from operations of $1.7 million has been included in our condensed consolidated financial statements. The unaudited pro forma financial results shown in the table below for the three and six months ended June 30, 2018 and 2017, combine the consolidated results of NN and Paragon Medical giving effect to the Paragon Medical acquisition as if it had been completed on January 1, 2017, the beginning of the comparable prior annual reporting period presented. The unaudited pro forma financial results do not give effect to any of our other acquisitions that occurred after January 1, 2017, and do not include any anticipated synergies or other assumed benefits of the Paragon Medical acquisition. This unaudited pro forma financial information is presented for informational purposes only and is not indicative of future operations or results had the Paragon Medical acquisition been completed as of January 1, 2017. The unaudited pro forma financial results include certain adjustments for additional depreciation and amortization expense based upon the fair value step-up and estimated useful lives of Paragon Medical depreciable fixed assets and definite-life amortizable assets acquired. The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results. The impact of adopting ASC 606 has been included based on an adoption date of January 1, 2018.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Pro forma net sales | $ | 210,902 |  |  | $ | 193,578 |  |  | $ | 420,731 |  |  | $ | 384,846 |
Pro forma income (loss) from continuing operations | $ | (12,017 | ) |  | $ | (29,092 | ) |  | $ | (20,078 | ) |  | $ | (44,238 | )
Pro forma net income (loss) | $ | (12,017 | ) |  | $ | (23,856 | ) |  | $ | (20,078 | ) |  | $ | (33,484 | )
Basic income (loss) from continuing operations per share | $ | (0.43 | ) |  | $ | (1.06 | ) |  | $ | (0.73 | ) |  | $ | (1.62 | )
Diluted income (loss) from continuing operations per share | $ | (0.43 | ) |  | $ | (1.06 | ) |  | $ | (0.73 | ) |  | $ | (1.62 | )
Unaudited pro forma results for the six months ended June 30, 2017, include $14.8 million of inventory fair value adjustments, financing, integration, and transaction costs, net of tax, directly attributable to the acquisition which will not have an ongoing impact. No such costs are present in the unaudited pro forma results for the three months ended June 30, 2017.

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration